Busse, William W.
Maspero, Jorge F.
Rabe, Klaus F.
Papi, Alberto
Wenzel, Sally E.
Ford, Linda B.
Pavord, Ian D.
Zhang, Bingzhi
Staudinger, Heribert
Pirozzi, Gianluca
Amin, Nikhil
Akinlade, Bolanle
Eckert, Laurent
Chao, Jingdong
Graham, Neil M. H.
Teper, Ariel
Clinical trials referenced in this document:
Documents that mention this clinical trial
S49 Dupilumab improves lung function across baseline disease characteristics in patients with evidence of type 2 inflammation at baseline: the LIBERTY ASTHMA QUEST study
https://doi.org/10.1136/thorax-2019-btsabstracts2019.55
S86 Long-term assessment of exacerbations and lung function in the LIBERTY ASTHMA TRAVERSE study, stratified by lung function improvements at the end of the phase 3 LIBERTY ASTHMA QUEST parent study
https://doi.org/10.1136/thorax-2021-btsabstracts.92
S118 Dupilumab efficacy is not affected by prior asthma exacerbation status in LIBERTY ASTHMA TRAVERSE open-label extension study
https://doi.org/10.1136/thorax-2023-btsabstracts.124
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
https://doi.org/10.1016/s0140-6736(16)30307-5
P44 Dupilumab reduces exacerbations and improves lung function in uncontrolled, moderate-to-severe asthma patients regardless of prior exacerbation history in the phase 3 LIBERTY ASTHMA QUEST study
https://doi.org/10.1136/thorax-2018-212555.202
S78 Dupilumab reduces risk of severe exacerbations and improves FEV1 regardless of baseline disease severity in patients with uncontrolled, moderate-to-severe asthma: data from the phase 3 LIBERTY ASTHMA QUEST study
https://doi.org/10.1136/thorax-2018-212555.84
S31 Dupilumab reduces severe exacerbations across baseline disease characteristics in patients with elevated baseline type 2 biomarkers: the LIBERTY ASTHMA QUEST study
https://doi.org/10.1136/thorax-2019-btsabstracts2019.37
S127 Relation between change in type 2 biomarker levels and efficacy outcomes in patients with asthma treated with dupilumab
https://doi.org/10.1136/thorax-2022-btsabstracts.133
Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma
https://doi.org/10.1007/s12325-018-0702-4
S128 Baseline characteristics of patients with asthma treated with dupilumab in a real-world setting: results from the RAPID registry
https://doi.org/10.1136/thorax-2022-btsabstracts.134
P124 Stability of fractional exhaled nitric oxide levels as a biomarker in patients with uncontrolled asthma
https://doi.org/10.1136/thorax-2023-btsabstracts.276
S135 Dupilumab efficacy vs standard of care in patients with uncontrolled, persistent asthma – a meta analysis
https://doi.org/10.1136/thorax-2020-btsabstracts.140
S84 Long-term efficacy of dupilumab: 3-year data of QUEST patients with moderate-to-severe asthma enrolled in LIBERTY ASTHMA TRAVERSE
https://doi.org/10.1136/thorax-2021-btsabstracts.90
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
https://doi.org/10.1007/s40257-020-00577-1
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals
Article History
Received: 28 February 2018
First Online: 3 May 2018